Back to Search
Start Over
Assessing the Quality of CAR-T Cells Using ddPCR: CAR-T cell therapy development is a complex process that requires standardization.
- Source :
- BioPharm International; 2022 Special Issue, p4-7, 4p
- Publication Year :
- 2022
-
Abstract
- The article discusses that analytical tools such as droplet digital polymerase chain reaction, a technology platform used to quantify nucleic acids, can support chimeric antigen receptor (CAR)-T cell manufacturers in developing successful CAR-T cell products. It mentions that with the growth across the industry, CAR-T cell therapy development is a complex process that requires standardization, regulation, and meticulous quality control to generate safe and effective therapies reliably.
Details
- Language :
- English
- ISSN :
- 1542166X
- Database :
- Complementary Index
- Journal :
- BioPharm International
- Publication Type :
- Periodical
- Accession number :
- 159278335